MX2010001429A - Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco. - Google Patents

Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.

Info

Publication number
MX2010001429A
MX2010001429A MX2010001429A MX2010001429A MX2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A
Authority
MX
Mexico
Prior art keywords
ascorbic acid
reducing
nasal delivery
powdered medicament
induced toxicity
Prior art date
Application number
MX2010001429A
Other languages
English (en)
Inventor
Peter Lambert
Merkus W H M Franciscus
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of MX2010001429A publication Critical patent/MX2010001429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe el uso de ácido arcórbico en la elaboración de un medicamento en polvo para distribución nasal para aliviar la toxicidad, el medicamento comprende un agente activo tal como apomorfina que exhibe toxicidad a tejido ciliado.
MX2010001429A 2007-08-06 2008-08-04 Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco. MX2010001429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715285.3A GB0715285D0 (en) 2007-08-06 2007-08-06 Improvements in or relating to powdered medicaments for nasal delivery
PCT/GB2008/002648 WO2009019463A1 (en) 2007-08-06 2008-08-04 Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue

Publications (1)

Publication Number Publication Date
MX2010001429A true MX2010001429A (es) 2010-06-23

Family

ID=38529367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001429A MX2010001429A (es) 2007-08-06 2008-08-04 Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.

Country Status (14)

Country Link
US (1) US20110086875A1 (es)
EP (1) EP2187881A1 (es)
JP (1) JP2010535750A (es)
KR (1) KR20100044881A (es)
CN (1) CN101820874B (es)
AU (1) AU2008285473A1 (es)
BR (1) BRPI0815088A2 (es)
CA (1) CA2707292A1 (es)
EA (1) EA201070251A1 (es)
GB (1) GB0715285D0 (es)
MX (1) MX2010001429A (es)
NZ (1) NZ583767A (es)
WO (1) WO2009019463A1 (es)
ZA (1) ZA201001600B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016333486B2 (en) 2015-09-28 2022-02-03 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81258C (fi) * 1982-02-01 1990-10-10 Sandoz Ag Foerfarande foer framstaellning av en farmaceutisk komposition foer nasal administration.
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
BE1007402A5 (nl) * 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US5944012A (en) * 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6251599B1 (en) * 1998-11-06 2001-06-26 Selective Genetics, Inc. Stabilized nucleic acid compositions and methods of preparation and use thereof
JP5149470B2 (ja) * 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials

Also Published As

Publication number Publication date
ZA201001600B (en) 2012-08-29
US20110086875A1 (en) 2011-04-14
KR20100044881A (ko) 2010-04-30
WO2009019463A1 (en) 2009-02-12
CN101820874B (zh) 2012-12-26
EP2187881A1 (en) 2010-05-26
AU2008285473A1 (en) 2009-02-12
EA201070251A1 (ru) 2010-08-30
BRPI0815088A2 (pt) 2015-02-03
GB0715285D0 (en) 2007-09-12
CN101820874A (zh) 2010-09-01
JP2010535750A (ja) 2010-11-25
CA2707292A1 (en) 2009-02-12
NZ583767A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
MX2009010289A (es) Composiciones para administracion nasal.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
IN2012DN02805A (es)
IN2012DN01233A (es)
MX2010009336A (es) Composiciones farmaceuticas acuosas que contienen complejos de borato-poliol.
HK1142062A1 (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
HK1140940A1 (en) Titration of tapentadol
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
GB0625648D0 (en) Compounds
MY159865A (en) Aqueous insulin preparations containing methionine
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
MY167918A (en) Composition for use in the sublingual delivery of medicaments to humans
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
MX2015004362A (es) Derivados de ketamina.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
TW200738627A (en) Trialkylsilyl-indoles
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2009011900A (es) Curacion de herida diabetica.
MX2010001429A (es) Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.
ES2325291A1 (es) "uso de un extracto de silybum marianum"

Legal Events

Date Code Title Description
FG Grant or registration